Compare Stocks

Date Range: 

 Nutritional High InternationalChemesis International1933 Industries4Front VenturesAB Science
SymbolCNSX:CHALCNSX:CSIOTCMKTS:TGIFFOTCMKTS:FFNTFOTCMKTS:ABSCF
Price Information
Current PriceN/AN/A$0.06$1.03$16.00
50-Day Moving Average$0.00$0.00$0.07$1.08$15.86
52-Week Low$0.00$0.00$0.04$0.50$8.65
52-Week High$0.00$0.00$0.13$1.98$26.70
MarketRank™
Overall Score1.41.00.00.01.0
Analysis Score2.00.00.00.00.0
Community Score5.05.00.00.05.0
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.00.00.0
Earnings & Valuation Score0.00.00.00.00.0
Analyst Ratings
Consensus RecommendationStrong BuyN/AN/AN/ABuy
Consensus Price Target$2.46N/AN/AN/AN/A
% Upside from Price Target∞ upsideN/AN/AN/AN/A
Trade Information
Market CapN/AN/AN/AN/AN/A
BetaN/AN/AN/AN/AN/A
Average VolumeN/AN/A722,538869,9101,090
Sales & Book Value
Annual RevenueN/AN/AN/AN/AN/A
Price / SalesN/AN/AN/AN/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book ValueN/AN/AN/AN/AN/A
Price / BookN/AN/AN/AN/AN/A
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSN/AN/AN/AN/AN/A
Trailing P/E Ratio0.000.000.000.000.00
Forward P/E RatioN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/AN/A
Current RatioN/AN/AN/AN/AN/A
Quick RatioN/AN/AN/AN/AN/A
Ownership Information
Institutional Ownership PercentageN/AN/AN/AN/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
EmployeesN/A147,000147,00038093
Shares OutstandingN/AN/AN/AN/AN/A
Next Earnings DateN/AN/A11/29/2021 (Estimated)11/29/2021 (Estimated)N/A
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
AB Science receives Health Canada approval letter to commence Phase I/II trial of AB8939 in the ...AB Science receives Health Canada approval letter to commence Phase I/II trial of AB8939 in the ...
apnews.com - September 23 at 10:24 AM
AB Science receives Health Canada approval letter to commence Phase I/II trial of AB8939 in the treatment of Acute Myeloid Leukemia (AML)AB Science receives Health Canada approval letter to commence Phase I/II trial of AB8939 in the treatment of Acute Myeloid Leukemia (AML)
finance.yahoo.com - September 22 at 1:02 PM
AB Science announced that an abstract on the long-term survival of masitinib in ALS has been ...AB Science announced that an abstract on the long-term survival of masitinib in ALS has been ...
apnews.com - September 21 at 8:06 AM
AB Science announced that an abstract on the long-term survival of masitinib in ALS has been selected for a platform presentation at the Annual Meeting of the Spanish Society of NeurologyAB Science announced that an abstract on the long-term survival of masitinib in ALS has been selected for a platform presentation at the Annual Meeting of the Spanish Society of Neurology
finance.yahoo.com - September 20 at 3:34 PM
AB Science announced today that it has received authorization to resume patient enrollment in ...AB Science announced today that it has received authorization to resume patient enrollment in ...
apnews.com - September 17 at 9:04 AM
AB Science announced today that it has received authorization to resume patient enrollment in the phase 2 masitinib study of COVID-19 (AB20001)AB Science announced today that it has received authorization to resume patient enrollment in the phase 2 masitinib study of COVID-19 (AB20001)
finance.yahoo.com - September 16 at 2:58 PM
AB Science announced that it has received new authorizations to resume patient enrollment in ...AB Science announced that it has received new authorizations to resume patient enrollment in ...
apnews.com - September 14 at 12:59 PM
AB Science announced that it has received new authorizations to resume patient enrollment in ...AB Science announced that it has received new authorizations to resume patient enrollment in ...
apnews.com - September 14 at 12:59 PM
AB Science announced that it has received new authorizations to resume patient enrollment in its Phase 3 studies of masitinibAB Science announced that it has received new authorizations to resume patient enrollment in its Phase 3 studies of masitinib
finance.yahoo.com - September 14 at 12:59 PM
AB Science announced today that results from masitinib study AB12003 in prostate cancer have ...AB Science announced today that results from masitinib study AB12003 in prostate cancer have ...
apnews.com - September 14 at 6:50 AM
AB Science announced today that results from masitinib study AB12003 in prostate cancer have been presented at the 2021 American Urological AssociationAB Science announced today that results from masitinib study AB12003 in prostate cancer have been presented at the 2021 American Urological Association
finance.yahoo.com - September 13 at 3:42 PM
AB Science (OTCMKTS:ABSCF)  Shares Down 2% AB Science (OTCMKTS:ABSCF) Shares Down 2%
americanbankingnews.com - September 9 at 12:56 AM
AB Science announced today that latest clinical data on long-term survival analyses in ALS will be presented at the 2021 symposium on ALS/MNDAB Science announced today that latest clinical data on long-term survival analyses in ALS will be presented at the 2021 symposium on ALS/MND
finance.yahoo.com - September 2 at 2:37 PM
AB Science announces that it has received a second authorization to resume patient enrollment,AB Science announces that it has received a second authorization to resume patient enrollment,
apnews.com - August 25 at 4:44 PM
AB Science announces that it has received a second authorization to resume patient enrollment, in the Phase 3 study of masitinib in mastocytosisAB Science announces that it has received a second authorization to resume patient enrollment, in the Phase 3 study of masitinib in mastocytosis
finance.yahoo.com - August 25 at 4:44 PM
AB Science announces that it has received the first authorization to resume patient enrollment ...AB Science announces that it has received the first authorization to resume patient enrollment ...
apnews.com - August 23 at 4:34 PM
AB Science announced the publication of a pathogenic mechanism triggered by mast cells in the ...AB Science announced the publication of a pathogenic mechanism triggered by mast cells in the ...
apnews.com - August 19 at 5:11 PM
AB Science announced the publication of a pathogenic mechanism triggered by mast cells in the amyotrophic lateral sclerosis (ALS) spinal cord that can be targeted by masitinibAB Science announced the publication of a pathogenic mechanism triggered by mast cells in the amyotrophic lateral sclerosis (ALS) spinal cord that can be targeted by masitinib
finance.yahoo.com - August 19 at 5:11 PM
AB Science publishes a Q&A press release, following-up on its June 28, 2021 press release relating to an agreement with historical shareholdersAB Science publishes a Q&A press release, following-up on its June 28, 2021 press release relating to an agreement with historical shareholders
finance.yahoo.com - August 6 at 5:38 PM
AB Science announced that results from its Phase 3 AB09004 study on mild to moderate ...AB Science announced that results from its Phase 3 AB09004 study on mild to moderate ...
apnews.com - July 29 at 1:09 PM
AB Science announced that results from its Phase 3 AB09004 study on mild to moderate Alzheimer’s disease have been presented at the AAICAB Science announced that results from its Phase 3 AB09004 study on mild to moderate Alzheimer’s disease have been presented at the AAIC
finance.yahoo.com - July 29 at 1:09 PM
AB Science today announced that an abstract reporting results from its Phase 3 AB09004 study on ...AB Science today announced that an abstract reporting results from its Phase 3 AB09004 study on ...
apnews.com - July 22 at 8:04 PM
AB Science today announced that an abstract reporting results from its Phase 3 AB09004 study on Alzheimer’s disease has been selected for an oral presentation at the annual Alzheimer’s Association International Conference (AAIC)AB Science today announced that an abstract reporting results from its Phase 3 AB09004 study on Alzheimer’s disease has been selected for an oral presentation at the annual Alzheimer’s Association International Conference (AAIC)
finance.yahoo.com - July 22 at 3:01 PM
AB Science announces the publication of new survival data showing that masitinib extended ...AB Science announces the publication of new survival data showing that masitinib extended ...
apnews.com - July 19 at 11:05 PM
AB Science announced today that it has signed an agreement with historical shareholders to implement a joint strategy to increase the value of masitinibAB Science announced today that it has signed an agreement with historical shareholders to implement a joint strategy to increase the value of masitinib
finance.yahoo.com - June 28 at 5:42 PM
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.